10 Small-Cap Biotechs with Key Catalysts for 2025 July List

dün

________________________________________
🔬 10 Small-Cap Biotechs with Key Catalysts for 2025 July List
________________________________________
1. Allogene Therapeutics (NASDAQ: ALLO)
• Catalyst: Phase 2 data for ALLO-501A (anti-CD19 CAR-T for large B-cell lymphoma) expected in H2 2025; potential pivotal data could lead to regulatory submission.
• Highlights: “Off-the-shelf” allogeneic CAR-T approach could transform cell therapy; watch for manufacturing/scalability updates.
________________________________________
2. Lixte Biotechnology (NASDAQ: LIXT)
• Catalyst: Phase 2 combo trial of LB-100 (PP2A inhibitor) + immunotherapy in solid tumors, with key data expected in late 2025.
• Highlights: If efficacy signals emerge, could prompt partnerships or additional trials.
________________________________________
3. Iovance Biotherapeutics (NASDAQ: IOVA)
• Catalyst: Commercial launch and sales uptake for AMTAGVI (lifileucel, first FDA-approved TIL therapy in advanced melanoma); upcoming label expansion studies in lung and cervical cancer.
• Highlights: Investor focus on launch ramp, real-world data, and new trial initiations in 2025.
________________________________________
4. RenBio (NASDAQ: RENB)
• Catalyst: Phase 1/2 data for RB-100 (bispecific antibody platform in solid tumors) expected mid-to-late 2025.
• Highlights: Pipeline progress and partnership announcements possible.
________________________________________
5. IGM Biosciences (NASDAQ: IGMS)
• Catalyst: Phase 2 data for IGM-2323 (CD20 x CD3 bispecific in non-Hodgkin lymphoma) expected early 2025; ongoing updates from IgM antibody platform.
• Highlights: Investor interest in clinical safety, efficacy, and potential for big pharma tie-ups.
________________________________________
6. Zura Bio (NASDAQ: ZURA)
• Catalyst: Phase 2b/3 trial start and topline data for tibulizumab (IL-7Ra mAb for autoimmune diseases) expected late 2025.
• Highlights: Focus on rare and orphan autoimmune indications.
________________________________________
7. INmune Bio (NASDAQ: INMB)
• Catalyst: Phase 2 Alzheimer’s data (XPro1595, targeting neuroinflammation) and oncology pipeline updates expected H1 2025.
• Highlights: Any signal in Alzheimer’s is high-impact; monitoring for FDA guidance.
________________________________________
8. Veru Inc (NASDAQ: VERU)
• Catalyst: Phase 3 trial results for enobosarm (oral SARM) in advanced breast cancer expected 2025; also, COVID/sepsis drug updates.
• Highlights: Regulatory clarity and partnership/M&A rumors are potential drivers.
________________________________________
9. Century Therapeutics (NASDAQ: IPSC)
• Catalyst: First-in-human data for iPSC-derived NK and CAR-T cell therapies, with updates expected at major meetings in 2025.
• Highlights: Platform validation and early efficacy/safety signals.
________________________________________
10. ProKidney (NASDAQ: PROK)
• Catalyst: Phase 3 pivotal data for REACT (cell therapy for chronic kidney disease/diabetes) due late 2025.
• Highlights: If positive, could become the first autologous cell therapy for kidney disease.
________________________________________
🔎 How to Monitor These Catalysts
• FDA submissions/meetings (ALLO, PROK, VERU)
• Clinical trial readouts (LIXT, RENB, IGMS, ZURA, INMB, IPSC)
• Commercial/launch data (IOVA)
• Partnership/M&A activity (IGMS, VERU, RENB)
________________________________________
📊 Summary Table
Ticker Company Upcoming Catalyst/Event Timeframe
ALLO Allogene Therapeutics Phase 2 LBCL CAR-T pivotal data H2 2025
LIXT Lixte Biotechnology LB-100 + immunotherapy Phase 2 data Late 2025
IOVA Iovance Biotherapeutics AMTAGVI launch data; label expansions Throughout 2025
RENB RenBio Bispecifics Phase 1/2 data Mid-to-late 2025
IGMS IGM Biosciences IGM-2323 Phase 2 data (lymphoma) Early 2025
ZURA Zura Bio Tibulizumab Phase 2b/3 topline data Late 2025
INMB INmune Bio Alzheimer’s/oncology trial updates H1 2025
VERU Veru Inc Enobosarm Phase 3 (breast cancer) 2025
IPSC Century Therapeutics First-in-human iPSC cell therapy data 2025
PROK ProKidney REACT Phase 3 (CKD) pivotal readout Late 2025
________________________________________
⚠️ Word of Caution
Small-cap biotech stocks can be extremely volatile, especially around catalyst events (trial data, FDA decisions). Sharp price swings—both up and down—are common. Always conduct your own research and be aware of the risks.

12 saat önce

Not

LIXT is UP 75% at market open today